person · Reporting owner
Kozicz-Stankiewicz Anna Ewa
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cibus, Inc.
Report date March 01, 2023 · Filed June 01, 2023
Section 16 reporting ended · disclosed 2023-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2030-08-04 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2030-08-04 | Direct | 5,000 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 5,000 · Balance 5,000 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2031-05-27 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-01 · Disposition to issuer · Disposed 12,761 · Balance 0 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2031-05-27 | Direct | 12,761 |
Reported balance
After 2023-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-01 · Grant · Acquired 12,761 · Balance 12,761 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-01 · Disposition to issuer · Disposed 34,900 · Balance 0 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-06-13 | Direct | 34,900 |
Reported balance
After 2023-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-01 · Grant · Acquired 34,900 · Balance 34,900 F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Jun 1, 2023 23:50 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 34,900 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001615594-23-000039 · primary_doc.xml · derivative · entry 6 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock · 34,900 shares Expires 2032-06-13 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 23:50 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 34,900 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001615594-23-000039 · primary_doc.xml · derivative · entry 5 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,900 shares Expires 2032-06-13 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 23:50 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 12,761 | Not disclosed Strike: $4.22 | Not disclosed |
DisclosureSEC source: 0001615594-23-000039 · primary_doc.xml · derivative · entry 4 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,761 Underlying: Common Stock · 12,761 shares Expires 2031-05-27 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 23:50 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 12,761 | Not disclosed Strike: $4.22 | Not disclosed |
DisclosureSEC source: 0001615594-23-000039 · primary_doc.xml · derivative · entry 3 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,761 shares Expires 2031-05-27 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 23:50 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 5,000 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0001615594-23-000039 · primary_doc.xml · derivative · entry 2 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-08-04 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 23:50 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 5,000 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0001615594-23-000039 · primary_doc.xml · derivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2030-08-04 F1 · kind: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · price: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:10 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 34,900 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001615594-22-000035 · primary_doc.xml · derivative · entry 2 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock · 34,900 shares Expires 2032-06-13 F1 · derivative.exercise_date: Option vests in full on the first anniversary of the date of the grant. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:37 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 12,761 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001615594-21-000066 · primary_doc.xml · derivative · entry 2 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,761 Underlying: Common Stock · 12,761 shares Expires 2031-05-27 F2 · derivative.exercise_date: Option vests in full on 5/27/2022. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:37 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 7,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-21-000066 · primary_doc.xml · nonDerivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,089 F1 · shares: The Restricted Stock Units vest in full on 5/27/2022. Read SEC document |
| August 04, 2020 Filed Aug 7, 2020 22:32 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 5,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001615594-20-000053 · primary_doc.xml · derivative · entry 2 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-08-04 F1 · derivative.exercise_date: Option vests as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. Read SEC document |
| July 02, 2020 Filed Aug 21, 2020 21:20 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 245 | $4.70 | $1,151.50 |
DisclosureSEC source: 0001615594-20-000062 · primary_doc.xml · nonDerivative · entry 2 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,165 F1 · shares: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| April 02, 2020 Filed Aug 21, 2020 21:20 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 245 | $2.87 | $703.15 |
DisclosureSEC source: 0001615594-20-000062 · primary_doc.xml · nonDerivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,410 F1 · shares: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 00:32 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 245 | $7.65 | $1,874.25 |
DisclosureSEC source: 0001615594-20-000001 · primary_doc.xml · nonDerivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,655 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 17:43 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 245 | $4.96 | $1,215.20 |
DisclosureSEC source: 0001615594-19-000035 · primary_doc.xml · nonDerivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 15:30 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 735 | $10.00 | $7,350.00 |
DisclosureSEC source: 0001615594-19-000030 · primary_doc.xml · nonDerivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,145 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. Read SEC document |
| July 18, 2019 Filed Jun 1, 2021 21:09 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 735 | $10.00 | $7,350.00 |
DisclosureSEC source: 0001615594-21-000059 · primary_doc.xml · nonDerivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,865 F1 · kind: The sale reported on the Form 4 originally filed was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019. F2 · balance_after: The number of shares beneficially owned by reporting person following the transaction reported on the Form 4 was incorrectly stated. Read SEC document |
| May 06, 2019 Filed May 9, 2019 00:31 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0001127602-19-017803 · form4.xml · derivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-05-06 F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 22:19 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 1,000 | $19.49 | $19,490.00 |
DisclosureSEC source: 0001127602-18-021068 · form4.xml · nonDerivative · entry 1 Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person. F2 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.